Leuco-Scint

Exametazime, the active ingredient in Leuco-Scint, is a radiopharmaceutical (leukocyte labeling agent) presented as a lyophilized kit for radiolabeling for intravenous use. It enables scintigraphic detection of infection and inflammation in patients undergoing diagnostic imaging. The kit is designed for preparation of technetium‑99m‑exametazime labeled leukocytes, which are then administered to visualize sites of active infection or inflammatory processes.

GNH USA supplies Leuco-Scint as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide and globally.

Exametazime, used as a leukocyte labeling agent for nuclear medicine imaging, assists in the evaluation of infectious and inflammatory conditions. - Infection detection: Enables scintigraphic localization of bacterial or fungal infection sites. - Inflammation assessment: Highlights areas of active inflammatory response for diagnostic clarification. - Osteomyelitis imaging: Provides targeted visualization of bone infection to guide treatment decisions. - Fever of unknown origin: Assists in identifying occult infectious foci when conventional work‑up is inconclusive.

Adverse reactions to Leuco-Scint are generally related to the radiopharmaceutical preparation or intravenous administration.

Common Side Effects: - Injection site discomfort: mild pain or erythema at the venipuncture site. - Transient flushing: brief warmth or redness sensation. - Nausea: mild, self‑limiting gastrointestinal upset. - Headache: mild to moderate, resolves without intervention. - Dizziness: brief sensation of light‑headedness. - Mild fever: low‑grade temperature rise.

Serious or Rare Side Effects: - Anaphylactic reaction: severe hypersensitivity requiring immediate medical attention. - Significant hypotension: marked blood pressure drop post‑injection. - Radiation‑induced tissue injury: unlikely but possible with improper handling.

When using Leuco-Scint, several precautions should be observed to ensure patient safety and product integrity. - Patient assessment: verify absence of active severe infection or uncontrolled inflammatory disease before administration. - Allergy screening: confirm no known hypersensitivity to technetium‑99m or exametazime. - Radiation safety: follow local regulations for handling and disposal of radioactive materials. - Hematologic evaluation: ensure adequate leukocyte count for labeling procedures. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Leuco-Scint may interact with other agents that affect leukocyte function or radiation exposure.

Major Interactions (Avoid): - Immunosuppressants: may reduce leukocyte labeling efficiency and imaging quality. - High‑dose steroids: can alter leukocyte migration, compromising diagnostic accuracy.

Moderate Interactions (Monitor Closely): - Other radiopharmaceuticals: cumulative radiation dose should be evaluated. - Contrast agents: may interfere with image interpretation if administered close in time. - Anticoagulants: monitor for bleeding at injection site.